Chargement en cours...
Should minimal residual disease negativity be the end point of myeloma therapy?
Publisher's Note: This article has a companion Counterpoint by Sonneveld. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.
Enregistré dans:
| Publié dans: | Blood Adv |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728451/ https://ncbi.nlm.nih.gov/pubmed/29296970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016000117 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|